TrialJournal of the European Academy of Dermatology and Venereology : JEADV2022

Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2.

A P Fernandez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.